Journals / Turkish Journal of Gastroenterology / 2003 / Cilt: 14 - Sayı: 3

Nimesulid'e bağlı fulminan hepatit

Nimesulide-induced fulminant hepatitis

Pages
208–210
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, patients receiving nimesulide should be frequently monitored with serial serum transaminases, beginning from the first week of intake.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:An 18-year-old boy was brought to the hospital with jaundice, confusion, abdominal discomfort and distension.
📊
Key Findings & Data:All of the signs, symptoms and laboratory abnormalities returned to normal after cessation of the nimesulide and supportive treatment, and he was discharged on the 15th day after admission.
💡
Conclusion & Impact:Therefore, patients receiving nimesulide should be frequently monitored with serial serum transaminases, beginning from the first week of intake.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç toksisitesi · Sulfonamidler · Karaciğer fonksiyon testleri

Abstract

An 18-year-old boy was brought to the hospital with jaundice, confusion, abdominal discomfort and distension. He had a his-tory of oral intake of nimesulide for three days. Clinical and laboratory findings were compatible with fulminant hepatitis. Exclusion of other causes of liver injury strongly favored drug-induced toxicity. All of the signs, symptoms and laboratory abnormalities returned to normal after cessation of the nimesulide and supportive treatment, and he was discharged on the 15th day after admission. This case differs from the other cases in the literature regarding the time of onset, and indicates that nimesulide may induce fulminant hepatitis in the first few days of administration. Therefore, patients receiving nimesulide should be frequently monitored with serial serum transaminases, beginning from the first week of intake.

Özet

Onsekiz yaşındaki bir erkek hasta hastanemize sarılık, konfüzyon, karında şişkinlik ve rahatsızlık hissi ile getirildi. Öyküsünden sırt ağrısı nedeniyle 3 gündür nimesulid aldığı öğrenildi. Klinik ve laboratuar bulgular fulminan hepatit tablosu ile uyumlu idi. Karaciğer hasarı yapabilecek diğer tüm nedenler ekarte edildikten sonra, ilaca bağlı hepatotoksisite düşünüldü. Nimesulid kesildikten sonra, destek tedavisi ile hastanın klinik tablosu düzeldi ve laboratuar parametreleri normal sınırlara döndü. Hasta yatışının 15'inci gününde şifa ile taburcu edildi. Bu vaka, hastalık tablosunun ortaya çıkış zamanı nedeniyle literatürde yayınlanan diğer nimesulide bağlı fulminan hepatitlerden farklılık göstermektedir. Nimesulid başlandıktan sonra ilk birkaç günde fulminan hepatit gelişebileceği ve nimesulid başlanan hastalarda ilk birkaç günden itibaren karaciğer enzimlerinin kontrol edilmesi gerekmektedir.

🔖

Cite This Article

ÖZGÜR, O., HACIHASANOĞLU, A., KARTI, S. S., OVALI, E. (2003). Nimesulid'e bağlı fulminan hepatit. Turkish Journal of Gastroenterology, Cilt: 14 - Sayı: 3, 208–210. https://ajindex.com/articles/410476

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14
  2. Rabinovitz M, Von Thiel DH. Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992; 87: 1696
  3. Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431-54
  4. Pasquale G, Scaricabarozzi I, D'Agostino R, et al. An assessment of the efficacy and tolerability of nimesulide vs paracetamol in children after adenotonsillectomy. Drugs 1993; 46: 234-7
  5. Schattner A, Sokolovskaya N, Cohen J. Fatal hepatitis and renal failure during treatment with nimesulide. J Intern Med 2000; 247: 153-5
  6. McCormick PA, Kennedy F, Curry M, Traynor O. COX 2 inhibitor and fulminant hepatic failure. Lancet 1999; 353: 40-1
  7. Andrade RJ, Lucena MI, Fernandez MC, Gonzalez M. Fatal hepatitis associated with nimesulide. J Hepatol 2000; 32: 174
  8. Merlani G, Fox M, Oehen HP, et al. Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001; 57: 321-6
  9. Van Steenbergen W, Peeters P, De Bondt J, et al. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol 1998; 29: 135-41
  10. Romero Gomez M, Nevado Santos M, Otero Fernandez MA, et al. Acute cholestatic hepatitis induced by nimesulide (letter). Liver 1999; 19: 164-5
  11. Fossaluzza V, Montagnani G. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double-blind trial versus naproxen. J Int Med Res 1989; 17: 295-303
  12. Danan G. Causality assessment of drug-induced liver injury. Hepatology working group. J Hepatol 1988; 7: 132-6
  13. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30
  14. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26: 23-30.